Back to All

Dr. Markus Eckstein shares a lab perspective on the impacts of a DXRX Collaboration

31 March, 2022

Featured

In March 2021, Diaceutics offered labs a collaboration opportunity via DXRX – The  Diagnostic Network®. The collaboration was an open call for FFPE tissue blocks to help Canadian Pathology Quality Assurance (CPQA-AQCP) build a small tissue microarray for the purpose of NTRK IHC proficiency testing as well as providing NTRK IHC validation assistance.

The focus of the collaboration with labs was to curate secretory breast carcinoma and/or salivary MASC blocks due to the higher incidence of NTRK Fusions in these tumours. Participating labs benefited from working with a renowned global EQA/ PT provider to support NTRK IHC proficiency testing and were eligible for free participation in the CPQA pan-TRK EQA program if the lab already offered an NTRK IHC service. The labs also received access to TMA slides and assistance for labs who wished to develop and validate Pan-TRK IHC.

Click here to read about Dr. Markus Eckstein's (MD. Institute of Pathology, University Hospital Erlangen, Germany) experience as a lab working on the DXRX Collaboration – NTRK IHC proficiency testing. https://www.diaceutics.com/uploads/dr-markus-eckstein-shares-a-lab-perspective-on-the-impacts-of-a-dxrx-collaboration-ntrk-ihc-proficiency-testing 

To learn more about how a DXRX collaboration can help your lab solve real-world testing challenges ensuring every patient gets the treatment they deserve, click here:  DXRX For Labs - Diaceutics

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny